智通财经APP讯，硕世生物(688399.SH)发布公告，公司产品猴痘病毒核酸检测试剂盒(荧光PCR法)于近 日被列入世界卫生组织(英文全称"World Health Organization"，以下简称 "WHO")应急使用清单(英文全 称"EmergencyUseListing"，以下简称"EUL")。 ...

Core Viewpoint - The company’s monkeypox virus nucleic acid testing kit (fluorescent PCR method) has been included in the WHO Emergency Use Listing as of December 3, indicating recognition from WHO and providing a basis for procurement, which may facilitate the product's promotion and sales in overseas markets [1] Group 1 - The inclusion in the WHO list has a procurement period of one year unless special circumstances arise [1] - The recognition by WHO can serve as a reference for potential buyers, enhancing the product's credibility in international markets [1] - Actual sales are subject to various factors including overseas policies, demand, and competition, leading to uncertainty in sales scale [1] Group 2 - The company is currently unable to predict the impact of this development on future performance [1]

人民财讯12月7日电，硕世生物(688399)12月7日公告，公司产品猴痘病毒核酸检测试剂盒(荧光PCR法) 于近日被列入世界卫生组织(简称"WHO")应急使用清单。 ...

证券代码：688399 证券简称：硕世生物 公告编号：2025-048 二、 对公司的影响 公司上述产品被列入 WHO EUL，表明 WHO 对公司产品的 认可和肯定，可为 WHO 成员国和各意向采购方提供采购依据， 对公司猴痘病毒核酸检测试剂盒（荧光 PCR 法）产品在相关海 外市场的推广和销售起到推动作用。 江苏硕世生物科技股份有限公司 关于自愿披露公司产品列入 WHO 应急使用清单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"）产品 猴痘病毒核酸检测试剂盒（荧光PCR法）于近日被列入世界卫生 组 织 （ 英 文 全 称 "World Health Organization" ， 以 下 简 称 "WHO"）应急使用清单（英文全称"Emergency Use Listing"， 以下简称"EUL"）。具体情况如下： 1 获批主体 Jiangsu Bioperfectus Technologies Co., Ltd 江苏硕世生物科技股份有限公司 产品名称 Monk ...

Core Viewpoint - The announcement details the renewal of the "Consistent Action Agreement" among the actual controllers of Jiangsu Shuoshi Biotechnology Co., Ltd., aimed at ensuring stable governance and operational continuity of the company [1][2]. Group 1: Background of the Agreement - The actual controllers, Fang Yongsheng, Liang Xilin, and Wang Guoqiang, collectively control 27.53% and 3.81% of the company's shares through various partnerships, with Fang Yongsheng serving as the honorary chairman and Wang Guoqiang as the chairman and general manager [1][2]. - The agreement was initially signed before the company's IPO and has been renewed on December 5 for the years 2022, 2023, 2024, and now 2025 to promote stable development based on shared goals [2]. Group 2: Main Content of the Agreement - The parties agree to act consistently in decision-making regarding the company, maintaining alignment in exercising their shareholder rights and responsibilities [3][4]. - They commit to cooperating actively in significant company decisions and adhering to relevant legal obligations as consistent action persons [4]. - The agreement is effective for twelve months from the date of signing [5]. Group 3: Impact of the Agreement - The renewal of the agreement does not change the actual control of the company, which remains with Fang Yongsheng, Liang Xilin, and Wang Guoqiang, ensuring stability in control and continuity in strategic and operational policies [6].

格隆汇12月5日丨硕世生物(688399.SH)公布，公司于2025年12月5日收到公司实际控制人房永生先生、 梁锡林先生、王国强先生关于续签《一致行动协议》的通知。鉴于各方在2024年12月5日签署续签的 《一致行动协议》已到期，为完善公司治理，保证公司经营的连续性和稳定性，实现对公司实质且有效 的控制，各方续签《一致行动协议》。 ...

证券代码：688399 证券简称：硕世生物 公告编号：2025-047 江苏硕世生物科技股份有限公司 房永生、梁锡林通过绍兴闰康生物医药股权投资合伙企业(有 限合伙)共同控制公司 27.53%股权，房永生、梁锡林通过泰州硕 源企业管理咨询合伙企业（有限合伙）、泰州硕康企业管理咨询合 伙企业（有限合伙）共同控制公司 3.81%股份，房永生通过泰州 硕鑫企业管理咨询合伙企业（有限合伙）、泰州硕科企业管理咨询 合伙企业（有限合伙）、泰州硕和企业管理咨询合伙企业（有限合 伙）控制公司 0.90%股份，房永生先生为公司名誉董事长、董事、 董事会战略委员会主任委员，王国强先生持有公司 8.73%股权且 担任公司的董事长兼总经理，长期管理公司的生产经营。 上述三人于公司首次公开发行股票并上市前签署了《一致行 动协议》，并分别于 2022 年 12 月 5 日、2023 年 12 月 5 日、2024 年 12 月 5 日续签了《一致行动协议》。为促进公司持续稳健发展， 基于共同理念，经充分沟通协商，房永生、梁锡林和王国强于 2025 年 12 月 5 日续签了《一致行动协议》。 二、本次续签《一致行动协议》的主要内容 甲方 ...

格隆汇12月5日丨硕世生物(688399.SH)公布，公司于2025年12月5日收到公司实际控制人房永生先生、 梁锡林先生、王国强先生关于续签《一致行动协议》的通知。鉴于各方在2024年12月5日签署续签的 《一致行动协议》已到期，为完善公司治理，保证公司经营的连续性和稳定性，实现对公司实质且有效 的控制，各方续签《一致行动协议》。 ...

证券日报网讯12月3日，硕世生物在互动平台回答投资者提问时表示，截至2025年11月20日，公司股东 总数7710户。 ...

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [6][54]. Core Viewpoints - The IVD market is expected to benefit from a recent policy initiative aimed at enhancing the adaptability of supply and demand for consumer goods, with a focus on high-end medical devices and efficient IVD equipment [5][53]. - The domestic biochemical diagnostics sector has largely overcome reliance on foreign technologies, indicating a completed process of localization [6][54]. - The report emphasizes the shift towards home health management, moving from a treatment-centered to a prevention-centered approach, which is expected to create a trillion-yuan integrated market [5][53]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 2.67%, with the IVD sector increasing by 2.63% during the week [2][12]. - The IVD sector's current PE ratio is 39.84X, with a PB ratio of 1.85X, reflecting a slight increase from the previous week [4][33]. Company Performance - Notable performers in the medical services sector include Haobio (+14.3%), Shuoshi Biological (+13.6%), and Innotech (+13.3%) [3][29]. - Underperformers include *ST Dongyang (-7.2%) and New Industry (-5.7%) [3][29]. Investment Recommendations - The report suggests focusing on companies in the IVD sector that cater to home consumption scenarios, such as Shengxiang Biological and Sannuo Biological [5][54]. - It highlights the importance of monitoring the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics like PCR [6][54].